Extracellular vesicles as nanomedicine: Hopes and hurdles in clinical translation

Thierry Burnouf, Vibhuti Agrahari, Vivek Agrahari

研究成果: 雜誌貢獻文章

摘要

The clinical development of cell therapies is revealing that extracellular vesicles (EVs) may become very instrumental as subcellular therapeutic adjuncts in human medicine. EVs are released by various types of cells, grown in culture, such as mesenchymal stromal cells, or obtained from patients or allogeneic donors. Some EV populations (especially species of exosomes and shed microvesicles) exhibit inherent roles in cell-cell communication, thanks to their ca. 30~1000-nm nanosize and the physiological expression of cell-specific markers on their lipid bilayer membranes. Biomedical engineers are now attempting to exploit this cellular crosstalk capacity to use EVs as smart drug delivery systems that display substantial benefits in targeting, safety, and pharmacokinetics compared to synthetic nanocarriers. In parallel, the development of a set of nano-instrumentation, biochemical tools, and preclinical assays needed for optimal characterization of both naïve and drug-loaded EVs is ongoing. Although many hurdles remain, owing to the complexity of EV populations, translation of this “subcellular therapy” platform into reality is at hand and may soon change the landscape of the therapeutic arsenal in place to treat human degenerative and metabolic pathologies as well as diseases like cancer. This article provides objective opinions, balanced between unrealistic hopes of the capacity of EVs to resolve multiple clinical issues and concrete hurdles that have to be overcome to ensure that EVs are not lost in the translation phase, so that EVs can fulfill their promise by becoming a reliable therapeutic modality.

原文英語
頁(從 - 到)8847-8859
頁數13
期刊International Journal of Nanomedicine
14
DOIs
出版狀態已發佈 - 一月 1 2019

指紋

Nanomedicine
Arsenals
Medical nanotechnology
Lipid bilayers
Pharmacokinetics
Pathology
Membrane Lipids
Crosstalk
Medicine
Assays
Cells
Concretes
Membranes
Engineers
Communication
Pharmaceutical Preparations
Exosomes
Drug Delivery Systems
Extracellular Vesicles
Lipid Bilayers

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry

引用此文

Extracellular vesicles as nanomedicine : Hopes and hurdles in clinical translation. / Burnouf, Thierry; Agrahari, Vibhuti; Agrahari, Vivek.

於: International Journal of Nanomedicine, 卷 14, 01.01.2019, p. 8847-8859.

研究成果: 雜誌貢獻文章

@article{e2c4300a777b4ccf91b42f49401b9053,
title = "Extracellular vesicles as nanomedicine: Hopes and hurdles in clinical translation",
abstract = "The clinical development of cell therapies is revealing that extracellular vesicles (EVs) may become very instrumental as subcellular therapeutic adjuncts in human medicine. EVs are released by various types of cells, grown in culture, such as mesenchymal stromal cells, or obtained from patients or allogeneic donors. Some EV populations (especially species of exosomes and shed microvesicles) exhibit inherent roles in cell-cell communication, thanks to their ca. 30~1000-nm nanosize and the physiological expression of cell-specific markers on their lipid bilayer membranes. Biomedical engineers are now attempting to exploit this cellular crosstalk capacity to use EVs as smart drug delivery systems that display substantial benefits in targeting, safety, and pharmacokinetics compared to synthetic nanocarriers. In parallel, the development of a set of nano-instrumentation, biochemical tools, and preclinical assays needed for optimal characterization of both na{\"i}ve and drug-loaded EVs is ongoing. Although many hurdles remain, owing to the complexity of EV populations, translation of this “subcellular therapy” platform into reality is at hand and may soon change the landscape of the therapeutic arsenal in place to treat human degenerative and metabolic pathologies as well as diseases like cancer. This article provides objective opinions, balanced between unrealistic hopes of the capacity of EVs to resolve multiple clinical issues and concrete hurdles that have to be overcome to ensure that EVs are not lost in the translation phase, so that EVs can fulfill their promise by becoming a reliable therapeutic modality.",
keywords = "Clinical translation challenge, Drug delivery, Exosome, Extracellular vesicle, Isolation and purification, Mesenchymal stromal cell, Microvesicle",
author = "Thierry Burnouf and Vibhuti Agrahari and Vivek Agrahari",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/IJN.S225453",
language = "English",
volume = "14",
pages = "8847--8859",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Extracellular vesicles as nanomedicine

T2 - Hopes and hurdles in clinical translation

AU - Burnouf, Thierry

AU - Agrahari, Vibhuti

AU - Agrahari, Vivek

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The clinical development of cell therapies is revealing that extracellular vesicles (EVs) may become very instrumental as subcellular therapeutic adjuncts in human medicine. EVs are released by various types of cells, grown in culture, such as mesenchymal stromal cells, or obtained from patients or allogeneic donors. Some EV populations (especially species of exosomes and shed microvesicles) exhibit inherent roles in cell-cell communication, thanks to their ca. 30~1000-nm nanosize and the physiological expression of cell-specific markers on their lipid bilayer membranes. Biomedical engineers are now attempting to exploit this cellular crosstalk capacity to use EVs as smart drug delivery systems that display substantial benefits in targeting, safety, and pharmacokinetics compared to synthetic nanocarriers. In parallel, the development of a set of nano-instrumentation, biochemical tools, and preclinical assays needed for optimal characterization of both naïve and drug-loaded EVs is ongoing. Although many hurdles remain, owing to the complexity of EV populations, translation of this “subcellular therapy” platform into reality is at hand and may soon change the landscape of the therapeutic arsenal in place to treat human degenerative and metabolic pathologies as well as diseases like cancer. This article provides objective opinions, balanced between unrealistic hopes of the capacity of EVs to resolve multiple clinical issues and concrete hurdles that have to be overcome to ensure that EVs are not lost in the translation phase, so that EVs can fulfill their promise by becoming a reliable therapeutic modality.

AB - The clinical development of cell therapies is revealing that extracellular vesicles (EVs) may become very instrumental as subcellular therapeutic adjuncts in human medicine. EVs are released by various types of cells, grown in culture, such as mesenchymal stromal cells, or obtained from patients or allogeneic donors. Some EV populations (especially species of exosomes and shed microvesicles) exhibit inherent roles in cell-cell communication, thanks to their ca. 30~1000-nm nanosize and the physiological expression of cell-specific markers on their lipid bilayer membranes. Biomedical engineers are now attempting to exploit this cellular crosstalk capacity to use EVs as smart drug delivery systems that display substantial benefits in targeting, safety, and pharmacokinetics compared to synthetic nanocarriers. In parallel, the development of a set of nano-instrumentation, biochemical tools, and preclinical assays needed for optimal characterization of both naïve and drug-loaded EVs is ongoing. Although many hurdles remain, owing to the complexity of EV populations, translation of this “subcellular therapy” platform into reality is at hand and may soon change the landscape of the therapeutic arsenal in place to treat human degenerative and metabolic pathologies as well as diseases like cancer. This article provides objective opinions, balanced between unrealistic hopes of the capacity of EVs to resolve multiple clinical issues and concrete hurdles that have to be overcome to ensure that EVs are not lost in the translation phase, so that EVs can fulfill their promise by becoming a reliable therapeutic modality.

KW - Clinical translation challenge

KW - Drug delivery

KW - Exosome

KW - Extracellular vesicle

KW - Isolation and purification

KW - Mesenchymal stromal cell

KW - Microvesicle

UR - http://www.scopus.com/inward/record.url?scp=85074895166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074895166&partnerID=8YFLogxK

U2 - 10.2147/IJN.S225453

DO - 10.2147/IJN.S225453

M3 - Article

AN - SCOPUS:85074895166

VL - 14

SP - 8847

EP - 8859

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

ER -